印度国际医学研究院与私营公司合作开发伤寒和型伤寒疫苗, 针对印度的高感染率. ICMR teams with private firms to develop typhoid and paratyphoid vaccines, targeting India's high infection rates.

印度医学研究理事会正与私营公司合作,开发一种伤寒和恶性磷疫苗,并将其商业化。 The Indian Council of Medical Research (ICMR) is collaborating with private companies to develop and commercialize a vaccine for typhoid and paratyphoid. ICMR 旨在验证和开发针对伤寒沙门氏菌和副伤寒等病原体的疫苗，选定的公司将支付 2% 的销售特许权使用费。 The ICMR aims to validate and develop the vaccine against pathogens like Salmonella Typhi and Paratyphi, with selected companies paying a 2% royalty on sales. 印度在2021年约有1 000万伤寒病例,这是全球最高的病例。 India had around 10 million typhoid cases in 2021, the highest globally. 印度国际医学研究院将在整个开发和商业化阶段提供技术支持. The ICMR will provide technical support throughout development and commercialization phases.